Admin
Sinetrol ®, from the French company Fytexia, is a citrus extract standardized in polyphenols helping to reduce the excess of fat mass.
Sinetrol acts by way of the exclusive mechanism of Fat Shredding Technology (FST). Without thermogenic effect, Sinetrol facilitates lipolysis trough the inhibition of phosphodiesterase PDE-4, the enzyme that catalyzes the hydrolysis of cyclic adenosine monophosphate (cAMP). Consequently, higher cAMP levels lead to an increased rate of triglyceride (TG) breakdown.
A new independent clinical trial confirms body composition improvement after supplementation with Sinetrol, a citrus polyphenol extract.
A new clinical study, published this month in the Journal of medicinal foods, releases proof of the efficacy of the citrus polyphenol-based ingredient Sinetrol on Asian population. The synergy of naringin and hesperidin is being studied for the first time on Asian population, associated with a low-calorie diet in a randomized, double-blind, placebo-control trial involving 86 South Korean subjects with 25<BMI<30.
The study has been run by the Research team of the department of <family medicine from Kangbuk Samsung Hospital, Seoul.
Participants took either Sinetrol-XPur in tablet form or a placebo once a day. Bodyweight, body fat percentage, body mass index (BMI), body fat mass, waist circumference, and various safety parameters were measured. After the 12-week intervention, a significant reduction was observed in the body fat mass (P = .030) by dual-energy X-ray absorptiometry (DEXA), body weight (P = .002), and BMI (P = .002) compared to the placebo. Safety profiles were not different between the two groups.
These results suggested that Sinetrol-Xpur significantly reduced body weight, body fat mass, and BMI in obese Korean subjects, which confirms the body composition benefits of Sinetrol-XPur in the Korean population.
The study has been funded by South Korean pharmaceutical leader RP Bio, which has been using the results of this study to submit to the MFDS (South Korean Ministry of Food & Drug Safety, formerly known as KFDA) a dossier supporting the application of Sinetrol on the improvement of body composition. Independent mechanistic and clinical study on South Korean population have been financed and piloted by RP Bio in Seoul to complete the scientific dossier developed by Fytexia, the French company developing the ingredient Sinetrol.
RP Bio has been receiving Individual authorization registration (IAR) on the 11th of September 2019 and is the only company in Korea able to commercialize Sinetrol in food supplements in South Korea. The South Korea MDFD’s health claim approval recognizes the ability of Sinetrol to “help reduce body fat” in overweight population.
Sinetrol is now being used in numerous new product developments sold over South Korea.
